Unknown

Dataset Information

0

Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.


ABSTRACT: Bacillus anthracis possesses an innate resistance to the antibiotic trimethoprim due to poor binding to dihydrofolate reductase (DHFR); currently, there are no commercial antibacterials that target this enzyme in B. anthracis. We have previously reported a series of dihydrophthalazine-based trimethoprim derivatives that are inhibitors for this target. In the present work, we have synthesized one compound (RAB1) displaying favorable 50% inhibitory concentration (54 nM) and MIC (< or =12.8 microg/ml) values. RAB1 was cocrystallized with the B. anthracis DHFR in the space group P2(1)2(1)2(1), and X-ray diffraction data were collected to a 2.3-A resolution. Binding of RAB1 causes a conformational change of the side chain of Arg58 and Met37 to accommodate the dihydrophthalazine moiety. Unlike the natural substrate or trimethoprim, the dihydrophthalazine group provides a large hydrophobic anchor that embeds within the DHFR active site and accounts for its selective inhibitory activity against B. anthracis.

SUBMITTER: Bourne CR 

PROVIDER: S-EPMC2704665 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.

Bourne Christina R CR   Bunce Richard A RA   Bourne Philip C PC   Berlin K Darrell KD   Barrow Esther W EW   Barrow William W WW  

Antimicrobial agents and chemotherapy 20090413 7


Bacillus anthracis possesses an innate resistance to the antibiotic trimethoprim due to poor binding to dihydrofolate reductase (DHFR); currently, there are no commercial antibacterials that target this enzyme in B. anthracis. We have previously reported a series of dihydrophthalazine-based trimethoprim derivatives that are inhibitors for this target. In the present work, we have synthesized one compound (RAB1) displaying favorable 50% inhibitory concentration (54 nM) and MIC (< or =12.8 microg/  ...[more]

Similar Datasets

| S-EPMC529193 | biostudies-literature
| S-EPMC89034 | biostudies-literature
| S-EPMC4249513 | biostudies-literature
| S-EPMC2934973 | biostudies-literature
| S-EPMC90431 | biostudies-literature
| S-EPMC1538648 | biostudies-literature
| S-EPMC105785 | biostudies-literature
| S-EPMC3618964 | biostudies-literature
| S-EPMC3530638 | biostudies-literature
| S-EPMC2645930 | biostudies-literature